JP2004520810A - 腫瘍の診断と治療のための組成物と方法 - Google Patents

腫瘍の診断と治療のための組成物と方法 Download PDF

Info

Publication number
JP2004520810A
JP2004520810A JP2002522275A JP2002522275A JP2004520810A JP 2004520810 A JP2004520810 A JP 2004520810A JP 2002522275 A JP2002522275 A JP 2002522275A JP 2002522275 A JP2002522275 A JP 2002522275A JP 2004520810 A JP2004520810 A JP 2004520810A
Authority
JP
Japan
Prior art keywords
seq
antibody
tat
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002522275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004520810A5 (enExample
Inventor
アシュケナジ，アヴィ，ジェー．
ゴッダード，オードリー
ゴドフスキー，ポール，ジェイ．
ガーニー，オースティン，エル．
ポラキス，ポール
ウィリアムス，ピー．ミッキー
ウッド，ウィリアム，アイ．
ディー． ウー，トーマス
チャン，ツオーミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/en
Priority claimed from PCT/US2001/006520 external-priority patent/WO2001068848A2/en
Priority claimed from PCT/US2001/017800 external-priority patent/WO2001093983A1/en
Priority claimed from PCT/US2001/019692 external-priority patent/WO2002000690A2/en
Priority claimed from PCT/US2001/021066 external-priority patent/WO2002008288A2/en
Priority claimed from PCT/US2001/021735 external-priority patent/WO2002008284A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2004520810A publication Critical patent/JP2004520810A/ja
Publication of JP2004520810A5 publication Critical patent/JP2004520810A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2002522275A 2000-08-24 2001-08-23 腫瘍の診断と治療のための組成物と方法 Pending JP2004520810A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/032678 WO2001040466A2 (en) 1999-12-01 2000-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/006520 WO2001068848A2 (en) 2000-03-01 2001-02-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/017800 WO2001093983A1 (en) 2000-06-02 2001-06-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/019692 WO2002000690A2 (en) 2000-06-23 2001-06-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
PCT/US2001/021066 WO2002008288A2 (en) 2000-07-20 2001-06-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/021735 WO2002008284A2 (en) 2000-07-20 2001-07-09 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
PCT/US2001/026626 WO2002016602A2 (en) 2000-08-24 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2005363921A Division JP2006104212A (ja) 2000-08-24 2005-12-16 腫瘍の診断と治療のための組成物と方法
JP2006252159A Division JP2007077155A (ja) 2000-08-24 2006-09-19 腫瘍の診断と治療のための組成物と方法

Publications (2)

Publication Number Publication Date
JP2004520810A true JP2004520810A (ja) 2004-07-15
JP2004520810A5 JP2004520810A5 (enExample) 2005-03-17

Family

ID=27567433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002522275A Pending JP2004520810A (ja) 2000-08-24 2001-08-23 腫瘍の診断と治療のための組成物と方法

Country Status (5)

Country Link
JP (1) JP2004520810A (enExample)
AU (2) AU8678501A (enExample)
CA (1) CA2420193A1 (enExample)
MX (1) MXPA03001643A (enExample)
WO (1) WO2002016602A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006166779A (ja) * 2004-12-15 2006-06-29 National Institute Of Advanced Industrial & Technology 核酸分解酵素
WO2006082851A1 (ja) * 2005-02-02 2006-08-10 The University Of Tokyo エピグリカニン関連ムチン
JP2009537154A (ja) * 2006-05-18 2009-10-29 モレキュラー プロファイリング インスティテュート， インコーポレイテッド 疾患状態に対する個別化された医学的介入を決定するためのシステムおよび方法
JP2014138588A (ja) * 2007-07-27 2014-07-31 Immatics Biotechnologies Gmbh 免疫療法用の新規免疫原性エピトープ
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
NZ535925A (en) * 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
EP2305710A3 (en) * 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
CA2498004C (en) * 2002-09-11 2013-06-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2006516192A (ja) * 2002-10-18 2006-06-29 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
AU2003299984A1 (en) * 2002-12-20 2004-07-22 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
US7893072B2 (en) 2003-07-02 2011-02-22 Genentech, Inc. Trp-p8 active compounds and therapeutic treatment methods
CN101010342A (zh) 2004-07-02 2007-08-01 健泰科生物技术公司 用于治疗非何杰金淋巴瘤的组合物和方法
US9221914B2 (en) 2007-12-26 2015-12-29 Biotest Ag Agents targeting CD138 and uses thereof
JP5817034B2 (ja) 2007-12-26 2015-11-18 バイオテスト・アクチエンゲゼルシヤフト Ｃｄ１３８を標的とする免疫複合体及びその使用
BRPI0821417A2 (pt) 2007-12-26 2015-06-16 Biotest Ag Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3909799A1 (de) * 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
AU764441B2 (en) * 1998-02-09 2003-08-21 Genset S.A. cDNAs encoding secreted proteins
DK1490386T3 (da) * 1998-03-10 2008-12-15 Genentech Inc Nyt polypeptid og nukleinsyrer kodende for dette
NZ510464A (en) * 1998-09-01 2004-05-28 Genentech Inc Further pro polypeptides and sequences thereof
JP2002527757A (ja) * 1998-10-19 2002-08-27 ダイアデクスアス・インコーポレーテッド 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006166779A (ja) * 2004-12-15 2006-06-29 National Institute Of Advanced Industrial & Technology 核酸分解酵素
WO2006082851A1 (ja) * 2005-02-02 2006-08-10 The University Of Tokyo エピグリカニン関連ムチン
JP2009537154A (ja) * 2006-05-18 2009-10-29 モレキュラー プロファイリング インスティテュート， インコーポレイテッド 疾患状態に対する個別化された医学的介入を決定するためのシステムおよび方法
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
JP2014138588A (ja) * 2007-07-27 2014-07-31 Immatics Biotechnologies Gmbh 免疫療法用の新規免疫原性エピトープ
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Also Published As

Publication number Publication date
MXPA03001643A (es) 2004-05-14
AU8678501A (en) 2002-03-04
AU2001286785B2 (en) 2006-08-17
WO2002016602A3 (en) 2003-02-06
WO2002016602A2 (en) 2002-02-28
CA2420193A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
JP4822710B2 (ja) 腫瘍の診断と治療のための組成物と方法
JP4912356B2 (ja) 腫瘍の診断及び治療のための組成物及び方法
US7514538B2 (en) Compositions and methods for the diagnosis and treatment of tumor
JP5587841B2 (ja) 造血系起源の腫瘍の治療のための組成物と方法
JP4703567B2 (ja) 膠細胞起源の腫瘍の診断と治療のための組成物と方法
JP2004520806A (ja) 腫瘍の診断と治療のための組成物と方法
JP2006516089A (ja) 腫瘍の診断と治療のための組成物と方法
US20060062727A1 (en) Compositions and methods for the diagnosis and treatment of tumor
JP2005536190A (ja) 腫瘍の診断と治療のための組成物と方法
JP2006516192A (ja) 腫瘍の診断と治療のための組成物と方法
JP2006510735A (ja) 腫瘍の診断と治療のための組成物と方法
JP2008137989A (ja) 腫瘍の診断と治療のための組成物と方法
JP2012046515A (ja) 腫瘍の診断と治療のための組成物と方法
JP2005528905A (ja) 腫瘍の診断と治療のための組成物と方法
JP2007519632A5 (enExample)
JP2004520810A (ja) 腫瘍の診断と治療のための組成物と方法
US8097700B2 (en) TAT294 polypeptides
JP2007521791A (ja) 腫瘍の診断と治療のための組成物と方法
JP2006104212A (ja) 腫瘍の診断と治療のための組成物と方法
JP2004520808A (ja) 腫瘍の診断と治療のための組成物と方法
JP2007512019A (ja) 腫瘍の診断と治療のための組成物と方法
JP2006516655A (ja) 腫瘍の診断と治療のための組成物と方法
US20050159588A1 (en) Compositions and methods for the diagnosis and treatment of tumor
KR100607610B1 (ko) 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US20070031901A1 (en) Compositions and methods for the diagnosis and treatment of tumor

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060628

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070424